<scp>SARS‐CoV</scp>‐2 infection in beta thalassemia: Preliminary data from the Italian experience

Motta, Irene; Amicis, Margherita Migone De; Pinto, Valeria; Balocco, Manuela; Longo, Filomena; Bonetti, F; Gianesin, Barbara; Graziadei, Giovanna; Cappellini, Maria Domenica; Franceschi, Lucia De; Piga, Antonio; Forni, Gian Luca

doi:10.1002/ajh.25840

Cited by 56 publications

(69 citation statements)

References 2 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, very little clinical experience of infected patients with haemoglobin disorders has been recorded 5 . Any statement on these subjects may be regarded as speculations; cautionary thoughts are however necessary, in view of the rapid spread of the virus and the possible factors which may render these patients vulnerable in front of this infection.…”

Section: General Considerations and Level Of Riskmentioning

confidence: 99%

“…Despite the fact that epidemiologic evidence concerning SARS‐CoV‐2 infection in patients with thalassaemia and sickle cell disease is currently lacking, 5 the COVID‐19 pandemic represents a significant challenge for haemoglobinopathy patients, their families and their attending physicians. Thalassaemia International Federation (TIF) follows closely the evolution of the COVID‐19 pandemic and compiles continuously the emerging scientific evidence relevant to the care of patients with haemoglobinopathies.…”

Section: Introductionmentioning

confidence: 99%

“…It should be stressed that as our yet limited knowledge on COVID‐19 progresses, 5 new evidence becomes continuously available that may challenge some of the information and guidance provided herein. The proposed measures and strategies may be useful as a blueprint for other disorders which require regular hospital visits, as well as for the timely adaptation of patient care during similar future pandemics.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation

Farmakis

Giakoumis

Cannon³

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Objectives Many patients with haemoglobinopathies, including thalassaemia and sickle cell disease, are at increased risk of developing severe complications from the coronavirus disease 2019 (COVID‐19). Although epidemiologic evidence concerning the novel coronavirus (SARS‐CoV‐2) infection in these patients is currently lacking, the COVID‐19 pandemic represents a significant challenge for haemoglobinopathy patients, their families and their attending physicians. Methods The present statement summarizes the key challenges concerning the management of haemoglobinopathies, with particular focus on patients with either transfusion‐dependent or non‐transfusion‐dependent thalassaemia, identifies the gaps in knowledge and suggests measures and strategies to deal with the pandemic, based on available evidence and expert opinions. Key areas covered include patients’ risk level, adaptation of haemoglobinopathy care, safety of blood transfusions, blood supply challenges, and lifestyle and nutritional considerations. Conclusions The proposed measures and strategies may be useful as a blueprint for other disorders which require regular hospital visits, as well as for the timely adaptation of patient care during similar future pandemics.

show abstract

Section: General Considerations and Level Of Riskmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation

Farmakis

Giakoumis

Cannon³

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…2 A study by Motta et al provided preliminary data from an Italian experience, showing that patients with thalassemia have mild clinical presentation of SARS-CoV-2 infection. 12 They included 10 cases of transfusion-dependent thalassemia (TDT) and one case of non-transfusion-dependent thalassemia (NTDT), all of whom had thalassemia-related comorbidities and were diagnosed with COVID-19. Six patients required hospitalization and none died.…”

mentioning

confidence: 99%

“…Except for one patient with myelosuppression, there was no increase in blood requirements. 12 A larger sample is required to better understand the impact of COVID-19 in thalassemia patients, but these data suggest that it may not be more severe than the general population.…”

mentioning

confidence: 99%